Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2019 | Story Zama Feni | Photo Charl Devenish
Dr Quinton Meyer and Marlena Visagie
National Control Laboratory Deputy Director, Dr Quinton Meyer (right), and Marlena Visagie, Quality Assurance Manager, at the laboratory within their facilities at the University of the Free State.

The University of the Free State-based National Control Laboratory for Biological Products (NCL) has maintained its esteemed status as a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) further endorsed its quality-management systems as of high standard according to the International Standards Organisation’s requirements.

The Director of the NCL, Professor Derek Litthauer, said their laboratory – which is also approved by the World Health Organisation (WHO) – has again achieved the international testing standards. The cherry on top was that the NCL also received a certificate of Good Manufacturing Compliance (GMP) from the South African Health Products Regulatory Authority (SAHPRA). 

NCL is for Africa and the World 

Some of the factors that make the NCL an esteemed institution, is the fact that it is one of 12 laboratories worldwide to perform vaccine testing for the WHO; the NCL is the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of SAHPRA. 

For example, Prof Litthauer said that the influenza vaccine batches currently available on the South African market, were tested by the NCL for quality before authorising their release for sale to the public. This process is followed for all human vaccines used in SA.

 “In our role as vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 
The NCL was one of the first full members of the WHO NCL Network for Biologicals, which consists of full and associate members of regulatory authorities from more than 30 countries.

The NCL systems are world-class

Prof Litthauer said this achievement is recognition that their laboratory complies with specific international standards with respect to its quality-management system. 
“In practice, it means that the laboratory has all the quality systems in place to ensure high-quality test results. The GMP certification is a further step, meaning that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. It is a very strict certification.”

He further mentioned that the NCL is also licensed as a pharmaceutical manufacturer. “Although we do not manufacture, we have to comply with manufacturing standards.”
“It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications. It means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world,” he said.
The certification provides the South African Health Products Regulatory Authority, the World Health Organisation, and other national control laboratories around the world, with the confidence that the test results from the NCL can be trusted.


There can be no compromise for quality 

The NCL Quality Assurance Manager, Mrs Marlena Visagie, said, “It is essential that the NCL complies with the highest international quality-assurance standards to ensure that all the lot-release operations, such as manufacturing review and quality testing, are performed in a reliable and reproducible manner.”

“There can be no compromise when it comes to the quality of medicines which are made available to the public,” she said.

“What makes this special, is that the NCL does not only comply with international ISO/IEC standards for pharmaceutical testing, but also with the additional GMP standards required by a pharmaceutical manufacturer. This means that the NCL must ensure that all its operations, including everything from the way documents are compiled and stored, to the maintenance of equipment and infrastructure as well as staff competency, are performed according to international guidelines.”

All NCL staff share vision of excellence

Prof Litthauer said the NCL has a staff complement of 15 technical, administrative, and support staff.  Four staff members have PhDs, and the rest of the technical staff have master’s or bachelor’s degrees or are trained as medical technologists. “At the moment, our biggest problem is to get enough suitable space to expand our testing,” he said.

Prof Litthauer said, “All the staff members at the NCL share the vision of excellence, which makes this kind of achievement possible.”
The NCL will host the third annual meeting of the WHO NCL Network in November of this year and will then be reassessed again by the WHO as part of the normal three-year cycle of assessments.  

News Archive

UFS Chemistry wins dti award
2010-11-02

At the awards ceremony are, from the left: Director-General of Trade and Industry Mr Tshediso Matona, Prof. Andreas Roodt and the Deputy-Minister of Trade and Industry, Ms Bongi Maria Ntuli.
Photo: S Osman

The research group of Prof. Andreas Roodt, Head of the Department of Chemistry at the University of the Free State (UFS) in Bloemfontein, won the first prize in the category Development of Small Medium and Micro-Enterprises (SMME) at the annual Department of Trade and Industry’s (dti) award ceremony.

Prof. Roodt received the prize for the high-technology project Development of novel nuclear pharmaceuticals in the Technology and Human Resources for Industry Programme (THRIP).

The Deputy-Minister of Trade and Industry Bongi Maria Ntuli, and Director-General Tshediso Matona presented the prize at the gala dinner held at Gallagher Estate, Gauteng in October 2010.

The dti’s Annual Technology Awards recognise excellence in research and aim to raise awareness on the benefits of using technology to improve the competitiveness of enterprises, within the local and global arena. Individuals and organisations are recognised for their efforts in advancing and promoting technology interests and emerging enterprises.

The technology awards cover the achievements of three of the dti technology programmes collectively, namely THRIP, managed by the National Research Foundation (NRF); the Support Programme for Industrial Innovation (SPII) managed by the Industrial Development Corporation (IDC); and the Small Enterprise Development Agency (seda) Technology Programme (stp).

Prof. Roodt, also vice-president of the European Crystallographic Association, who has just returned from a series of lectures abroad after being elected Fellow of the Royal Society of Chemistry in the UK, has received funding in excess of R3 million over the past two years to set up a specialised laboratory for synthesising active compounds. Key partners in this project are Dr Gerdus Kemp from PETLabs Pharmaceuticals in Pretoria; Prof. Connie Medlen (pharmacologist), recently appointed affiliate professor at UFS Chemistry; as well as Prof. Deon Visser from the Inorganic Chemistry research group at the UFS.

The research aims to produce new nuclear medicinal agents for the early diagnosis of cancer, heart and brain defects, and even HIV/ Aids.

Two doctoral students, Alice Brink and Marietjie Schutte, are currently actively involved in this project. They are the recipients of prestige scholarships introduced by the UFS Rector and Vice-Chancellor, Prof. Jonathan Jansen, under the UFS Research Initiative (the Advanced Biomolecular Systems Cluster) to complete their Ph.D. studies.

Media Release
Issued by: Lacea Loader
Director: Strategic Communication (actg)
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl@ufs.ac.za  
2 November 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept